Vancouver, British Columbia and Sacramento, California — February 4, 2026 — Leads & Copy — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) has completed a non-brokered private placement financing and entered a debt settlement agreement.
The medical device company, which is commercializing imaging-based products for more accurate breast cancer screening, diagnosis, and treatment, announced it had completed the financing further to its January 28, 2026, announcement. The company also announced it has entered into a debt settlement agreement with a lender to settle outstanding interest payable pursuant to a promissory note originally issued by the company.
The company issued 1.2 million units at a price of $0.25 per unit for gross proceeds of $300,000. Each unit consists of one common share and one transferable warrant. Each warrant entitles the holder to purchase one additional share at a price of $0.25 per share for a period of three years from the closing of the offering.
Proceeds from the offering will be used for general working capital.
Completion of the offering is subject to a number of conditions, including receipt of all necessary regulatory approvals.
None of the securities issued in the offering will be registered under the United States Securities Act of 1933, as amended, and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
The company previously entered into a promissory note dated April 1, 2022, with the lender in the principal amount of $2 million. As of the date of the release, the company owed the lender $60,000 in accrued interest, representing three months of interest for the period from October to December 2025.
Pursuant to the agreement, the company will settle the interest through the issuance of 240,000 units at a price of $0.25 per unit, in full settlement of the interest. Each unit consists of one common share and one transferable warrant, and each warrant entitles the holder to purchase one additional share at a price of $0.25 per share for a period of three years from the date of issuance.
All securities to be issued in connection with the offering and interest settlement will be subject to a statutory hold period of four months and one day, in accordance with applicable securities laws.
Completion of the interest settlement remains subject to the approval of the Canadian Securities Exchange.
More information about Izotropic Corporation can be found on its corporate website and by reviewing its profile on SEDAR at sedarplus.ca.
Source: Izotropic Corporation
